2023 World Conference on Lung Cancer (Posters)-P2.09. Gefitinib Maintenance After Definitive CCRT in EGFR mutant Stage III NSCLC: Single Arm, Open Label, Multicenter Phase 2 Trial

P2.09. Gefitinib Maintenance After Definitive CCRT in EGFR mutant Stage III NSCLC: Single Arm, Open Label, Multicenter Phase 2 Trial - PDF(Slides)

Back to course

Pdf Summary

A recent study conducted at the Asan Medical Center in Korea evaluated the effectiveness of Gefitinib maintenance treatment after definitive concurrent chemoradiotherapy (CCRT) in patients with stage III non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. The study was an open-label, single-arm, multicenter phase II trial, and included patients aged 19 or older who had received platinum-based CCRT.<br /><br />The primary endpoint of the study was progression-free survival (PFS), and the secondary endpoints were overall survival (OS) and safety. A total of 15 patients were included in the study, with a median age of 64. The majority of patients had stage IIIA cancer and adenocarcinoma as the tumor type. The most common EGFR mutations were L858R and 19 deletion.<br /><br />The results showed that the median PFS was 26.5 months, and the median OS was not reached during the study period. The overall response rate was 66.67%, and the disease control rate was 93.33%. The most common adverse event was skin rash, but no grade 3 or 4 toxicities were observed.<br /><br />Based on these findings, the study concludes that Gefitinib maintenance treatment after definitive CCRT demonstrated excellent PFS and OS in patients with EGFR-mutant stage III NSCLC. Furthermore, the treatment was well-tolerated with no unexpected toxicities.<br /><br />This study provides valuable insights into the use of Gefitinib as a maintenance treatment option for patients with EGFR-mutant NSCLC following CCRT. It suggests that this approach could potentially improve the outcomes and survival of patients with this specific type of lung cancer. Future research and larger clinical trials are warranted to confirm these findings and further optimize treatment strategies for patients with EGFR-mutant NSCLC.

Asset Subtitle

Yoonsil Jang

Meta Tag

Speaker Yoonsil Jang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Gefitinib

maintenance treatment

NSCLC

EGFR mutations

progression-free survival

overall survival

platinum-based CCRT

skin rash

adenocarcinoma

treatment strategies